Toshiba expands CT offerings with compact helical scanner
But pioneering 900S system process too costlyToshiba's helical CT technology is evolving at a rapid pace. Followingintroduction of the premium Xpress/SX system late last year (SCAN11/17/93), the vendor will add a mid-tier price point to its
But pioneering 900S system process too costly
Toshiba's helical CT technology is evolving at a rapid pace. Followingintroduction of the premium Xpress/SX system late last year (SCAN11/17/93), the vendor will add a mid-tier price point to its helicalline in 1994 with Xvision. Toshiba America Medical Systems willalso phase out sales of its pioneering fourth-generation, slip-ring-based900S system, introduced in 1986.
Japanese sales of Toshiba's compact Xvision scanner are slatedto begin in July. A 510(k) application to the Food and Drug Administrationfor U.S. market clearance should be filed this year, said DavidEaton, TAMS CT product manager.
Xvision is about half the size and nearly a third lighter thanstandard helical scanners. It uses the same console as Xpressand the non-helical Xpeed scanner but packs a redesigned gantry.Xvision could expand CT applications and market opportunitiesfor Toshiba. For instance, it might allow use of volumetric CTimaging in the operating room to guide surgery.
With the competitive market determining CT system price levels,the high cost of producing 900S has made the scanner less profitablefor the vendor. After selling its last two units in U.S. inventoryduring 1994, TAMS plans no further orders of 900S from Japan.The system will continue to be sold internationally.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
